SS 31.

SS 31 is a research compound in the mitochondrial & longevity peptides.

Mitochondria-derived peptides studied in metabolism and stress responses.

It draws interest for mitochondrial & longevity peptides.

C-tier evidence: some human evidence exists but isn't definitive.

What it is

SS-31, known generically as elamipretide and chemically as the tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2',6'-dimethyltyrosine), is a synthetic, cell-permeable, mitochondria-targeting peptide of the "Szeto-Schiller" (SS) aromatic-cationic class, originally discovered by Hazel Szeto and Peter Schiller at Cornell during opioid-peptide work. It is the lead clinical candidate of this class and, as elamipretide HCl, received its first regulatory approval in 2025. It is best understood as a mitochondrial protective/bioenergetic agent rather than a growth-factor or "anabolic" peptide.

How it works

SS-31 carries an alternating aromatic-cationic motif giving it a net positive charge that drives selective, concentration-dependent accumulation (reported >1000-fold over cytosol) in the inner mitochondrial membrane, where it binds reversibly to cardiolipin, an anionic phospholipid unique to that membrane. By associating with cardiolipin it is thought to stabilize cristae architecture, protect the cardiolipin-cytochrome c interaction and electron-transport-chain organization, support membrane potential and ATP synthesis, and reduce mitochondrial reactive oxygen species. Unlike a classic free-radical scavenger, current biophysical work (e.g., studies of its effect on bilayer surface electrostatics) frames its primary action as modulation of mitochondrial membrane structure/electrostatics rather than simple antioxidant chemistry. These mechanisms are well characterized in cell and tissue models; the downstream clinical consequences in humans remain only partially established.

What the evidence shows

The strongest human evidence is in Barth syndrome: based largely on the TAZPOWER program (an improvement in knee-extensor muscle strength taken as reasonably likely to predict clinical benefit), the FDA granted accelerated approval to elamipretide HCl (brand FORZINITY, Stealth BioTherapeutics) in September 2025 for Barth syndrome in patients weighing at least 30 kg, the first approved mitochondria-targeted peptide. In contrast, the larger Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy (Karaa et al., Neurology 2023, ~218 participants) FAILED its co-primary endpoints (6-minute walk test and Total Fatigue Score), though post hoc analyses suggested possible benefit in a mitochondrial-DNA replisome/maintenance subgroup, motivating the follow-up NuPOWER trial. Trials in heart failure (PROGRESS-HF) and dry age-related macular degeneration (ReCLAIM) likewise missed their primary endpoints. Most other indications (kidney injury, aging, Barth cardiac and broader neurodegeneration) rest on preclinical/animal data, so the human evidence base is narrow and, outside Barth syndrome, largely negative or unproven.

Safety considerations

Across clinical trials the most commonly reported adverse events have been injection-site reactions (pain, redness, swelling) consistent with subcutaneous administration, with milder reports of headache, dizziness, and nausea; published trial data generally did not show clinically significant changes in vital signs, routine labs, or ECG over extended dosing. However, long-term safety beyond the studied trial populations, and safety of non-pharmaceutical "research-use" material sold outside the approved product, are not established. Because the only rigorously studied, quality-controlled form is the FDA-approved prescription product, gray-market SS-31 carries additional unknowns around purity, sterility, and identity. This summary describes documented findings only and intentionally excludes any dosing or administration details.

Regulatory status

As elamipretide HCl (FORZINITY), SS-31 received FDA accelerated approval in September 2025 for Barth syndrome, making it the first approved mitochondria-targeted peptide; accelerated approval means continued approval may depend on confirmatory benefit. For all other uses (e.g., heart failure, mitochondrial myopathy, ophthalmic and "anti-aging" applications) it remains investigational or unproven, and material marketed as "SS-31" for research is not an FDA-approved drug for those purposes.

1. [1]Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial — Neurology, 2023; DOI 10.1212/WNL.0000000000207402 (Karaa et al.); PMC10382259
2. [2]Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — International Journal of Molecular Sciences, 2025; PMID 39940712; DOI 10.3390/ijms26030944
3. [3]Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY (elamipretide HCl) for Barth Syndrome — Stealth BioTherapeutics / PR Newswire, September 2025
4. [4]The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action — Journal of Biological Chemistry, 2020; PMC7247319

• Not FDA-approved; investigational.
• Outcomes in late-stage trials have been mixed; benefit is not established.

Stack fit

Why not B: held back by regulatory clarity.

Why not D: supported by preclinical depth, mechanism confidence.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• SS 31 is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Mitochondrial & longevity peptides class.
• Its principal mechanism is characterized in the literature.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The Mitochondrial peptide signalling mechanism
3. The preclinical evidence lane
4. Why Early, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently